Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 6/2016

01-12-2016 | Research Article

Drug utilization study of systemic antifungal agents in a Brazilian tertiary care hospital

Authors: Maria Clara Padovani de Souza, Andrezza Gouvêa dos Santos, Adriano Max Moreira Reis

Published in: International Journal of Clinical Pharmacy | Issue 6/2016

Login to get access

Abstract

Background The inappropriate use of systemic antifungal agents can result in unnecessary exposure, adverse events, increased microbial resistance and increased costs. Aim This study analysed the use of systemic antifungal agents and adherence to treatment guidelines for fungal infections. Setting A Brazilian tertiary hospital. Methods This cross-sectional study investigated 183 patients who were treated with systemic antifungals. Antifungal drugs were classified according to the fourth level of the Anatomical Therapeutic Chemical classification system. The appropriateness of treatments was analysed with respect to the indication, dose and potential drug–drug interactions. Descriptive and univariate statistical analyses were performed. The main outcome measure was the frequency of adherence to treatment guidelines for fungal infections. Results The number of established treatments was 320, with 163 (50.9 %) pre-emptive, 63 (19.7 %) targeted, 56 (17.5 %) empirical and 38 (11.9 %) prophylactic treatments. The overall adherence to the treatment guidelines was 29.4 %. The proportion of appropriate treatment considering indication, dosage and drug–drug interactions was 84.1, 67.8 and 47.2 %, respectively. The most commonly prescribed systemic antifungal agents were fluconazole in 170 (53.1 %), voriconazole in 43 (13.4 %) and amphotericin B deoxycholate in 36 (11.3 %) cases. Conclusion The study showed a low proportion of appropriate antifungal drug use; the dosage and drug–drug interactions criteria were the determining factors for the high percentage of non-adherence to treatment guidelines in the hospital. The profile of antifungal agents used showed the predominance of fluconazole as well as the use of new antifungal drugs.
Literature
1.
go back to reference Nivoix Y, Launoy A, Lutun P, Moulin JC, Phai Pang KA, Fornecker LM, et al. Adherence to recommendations for the use of antifungal agents in a tertiary care hospital. J Antimicrob Chemother. 2012;67:2506–13.PubMedCrossRef Nivoix Y, Launoy A, Lutun P, Moulin JC, Phai Pang KA, Fornecker LM, et al. Adherence to recommendations for the use of antifungal agents in a tertiary care hospital. J Antimicrob Chemother. 2012;67:2506–13.PubMedCrossRef
2.
go back to reference Metzke B, Neubauer WC, Hieke S, Jung M, Wäsch R, Engelhardt M. Use of systemic antifungals in daily clinical practice in the haematology and oncology setting: results of a prospective observational analysis. Pharmacoepidemiol Drug Saf. 2012;21:953–63.PubMedCrossRef Metzke B, Neubauer WC, Hieke S, Jung M, Wäsch R, Engelhardt M. Use of systemic antifungals in daily clinical practice in the haematology and oncology setting: results of a prospective observational analysis. Pharmacoepidemiol Drug Saf. 2012;21:953–63.PubMedCrossRef
3.
go back to reference Ramírez E, García-Rodríguez J, Borobia A, Ortega JM, Lei S, Barrios-Fernández A, et al. Use of antifungal agents in a pediatric and adult high-risk areas. Eur J Clin Microbiol Infect Dis. 2012;31:337–47.PubMedCrossRef Ramírez E, García-Rodríguez J, Borobia A, Ortega JM, Lei S, Barrios-Fernández A, et al. Use of antifungal agents in a pediatric and adult high-risk areas. Eur J Clin Microbiol Infect Dis. 2012;31:337–47.PubMedCrossRef
4.
go back to reference Gross BN, Steib-Bauert M, Kern WV, Knoth H, Borde JP, Krebs S, et al. Hospital use of systemic antifungal drugs: a multi-center surveillance update from Germany. Infection. 2015;43:423–9.PubMedCrossRef Gross BN, Steib-Bauert M, Kern WV, Knoth H, Borde JP, Krebs S, et al. Hospital use of systemic antifungal drugs: a multi-center surveillance update from Germany. Infection. 2015;43:423–9.PubMedCrossRef
5.
go back to reference Muñoz P, Rojas L, Cervera C, Garrido G, Fariñas MC, Valerio M, et al. Poor compliance with antifungal drug use guidelines by transplant physicians: a framework for educational guidelines and an international consensus on patient safety. Clin Transplant. 2012;26:87–96.PubMedCrossRef Muñoz P, Rojas L, Cervera C, Garrido G, Fariñas MC, Valerio M, et al. Poor compliance with antifungal drug use guidelines by transplant physicians: a framework for educational guidelines and an international consensus on patient safety. Clin Transplant. 2012;26:87–96.PubMedCrossRef
6.
go back to reference Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis. 2006;43:S3–14.CrossRef Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis. 2006;43:S3–14.CrossRef
7.
go back to reference Zarb P, Amadeo B, Muller A, Drapier N, Vankerckhoven V, Davey P, et al. Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009. Clin Microbiol Infect. 2012;18:E389–95.PubMedCrossRef Zarb P, Amadeo B, Muller A, Drapier N, Vankerckhoven V, Davey P, et al. Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009. Clin Microbiol Infect. 2012;18:E389–95.PubMedCrossRef
8.
go back to reference Valerio M, Muñoz P, Rodríguez CG, Caliz B, Padilla B, Fernández-Cruz A, et al. Antifungal stewardship in a tertiary-care institution: a bedside intervention. Clin Microbiol Infect. 2015;21:492.e1–9.CrossRef Valerio M, Muñoz P, Rodríguez CG, Caliz B, Padilla B, Fernández-Cruz A, et al. Antifungal stewardship in a tertiary-care institution: a bedside intervention. Clin Microbiol Infect. 2015;21:492.e1–9.CrossRef
9.
go back to reference López-Medrano F, San Juan R, Lizasoain M, Catalán M, Ferrari JM, Chaves F, et al. A non-compulsory stewardship programme for the management of antifungals in a university-affiliated hospital. Clin Microbiol Infect. 2013;19:56–61.PubMedCrossRef López-Medrano F, San Juan R, Lizasoain M, Catalán M, Ferrari JM, Chaves F, et al. A non-compulsory stewardship programme for the management of antifungals in a university-affiliated hospital. Clin Microbiol Infect. 2013;19:56–61.PubMedCrossRef
10.
go back to reference Mondain V, Lieutier F, Hasseine L, Gari-Toussaint M, Poiree M, Lions C, et al. A 6-year antifungal stewardship programme in a teaching hospital. Infection. 2013;41:621–8.PubMedCrossRef Mondain V, Lieutier F, Hasseine L, Gari-Toussaint M, Poiree M, Lions C, et al. A 6-year antifungal stewardship programme in a teaching hospital. Infection. 2013;41:621–8.PubMedCrossRef
11.
go back to reference Colombo AL, Guimarães T, Camargo LF, Richtmann R, Queiroz-Telles F, et al. Brazilian guidelines for the management of candidiasis—a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical. Braz J Infect Dis. 2013;17:283–312.PubMedCrossRef Colombo AL, Guimarães T, Camargo LF, Richtmann R, Queiroz-Telles F, et al. Brazilian guidelines for the management of candidiasis—a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical. Braz J Infect Dis. 2013;17:283–312.PubMedCrossRef
12.
go back to reference Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35.PubMedCrossRef Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35.PubMedCrossRef
13.
go back to reference Sutepvarnon A, Apisarnthanarak A, Camins B, Mondy K, Fraser VJ. Inappropriate use of antifungal medications in a tertiary care center in Thailand: a prospective study. Infect Control Hosp Epidemiol. 2008;29:370–3.PubMedCrossRef Sutepvarnon A, Apisarnthanarak A, Camins B, Mondy K, Fraser VJ. Inappropriate use of antifungal medications in a tertiary care center in Thailand: a prospective study. Infect Control Hosp Epidemiol. 2008;29:370–3.PubMedCrossRef
14.
go back to reference Garey KW, Pai MP, Suda KJ, Turpin RS, Rege MD, Mingo DE, et al. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf. 2007;16:919–27.PubMedCrossRef Garey KW, Pai MP, Suda KJ, Turpin RS, Rege MD, Mingo DE, et al. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf. 2007;16:919–27.PubMedCrossRef
15.
go back to reference Salci TP, Gimenes M, dos Santos CA, Svidzinski TI, Caparroz-Assef SM. Utilization of fluconazole in an intensive care unit at a university hospital in Brazil. Int J Clin Pharm. 2013;35:176–80.PubMedCrossRef Salci TP, Gimenes M, dos Santos CA, Svidzinski TI, Caparroz-Assef SM. Utilization of fluconazole in an intensive care unit at a university hospital in Brazil. Int J Clin Pharm. 2013;35:176–80.PubMedCrossRef
17.
go back to reference Maertens J, Marchetti O, Herbrecht R, Cornely OA, Flückiger U, Frêre P, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant. 2011;46:709–18.PubMedCrossRef Maertens J, Marchetti O, Herbrecht R, Cornely OA, Flückiger U, Frêre P, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant. 2011;46:709–18.PubMedCrossRef
20.
go back to reference Micallef C, Aliyu SH, Santos R, Brown NM, Rosembert D, Enoch DA. Introduction of an antifungal stewardship programme targeting high-cost antifungals at a tertiary hospital in Cambridge, England. J Antimicrob Chemother. 2015;70:1908–11.PubMed Micallef C, Aliyu SH, Santos R, Brown NM, Rosembert D, Enoch DA. Introduction of an antifungal stewardship programme targeting high-cost antifungals at a tertiary hospital in Cambridge, England. J Antimicrob Chemother. 2015;70:1908–11.PubMed
21.
go back to reference Enoch DA, Idris SF, Aliyu SH, Micallef C, Sule O, Karas JA. Micafungin for the treatment of invasive aspergillosis. J Infect. 2014;68:507–26.PubMedCrossRef Enoch DA, Idris SF, Aliyu SH, Micallef C, Sule O, Karas JA. Micafungin for the treatment of invasive aspergillosis. J Infect. 2014;68:507–26.PubMedCrossRef
22.
go back to reference Cornely OA, Meems L, Herbrecht R, Viscoli C, van Amsterdam RG, Ruhnke M. Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis. Mycoses. 2015;58:58–64.PubMedCrossRef Cornely OA, Meems L, Herbrecht R, Viscoli C, van Amsterdam RG, Ruhnke M. Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis. Mycoses. 2015;58:58–64.PubMedCrossRef
23.
go back to reference Garey KW, Neuhauser MM, Bearden DT, Cannon JP, Lewis RE, Gentry LO, et al. Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. Mycoses. 2006;49:226–31.PubMedCrossRef Garey KW, Neuhauser MM, Bearden DT, Cannon JP, Lewis RE, Gentry LO, et al. Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. Mycoses. 2006;49:226–31.PubMedCrossRef
24.
go back to reference Trevisan DD, Silva JB, Oliveira HC, Secoli SR, Lima MH. Prevalence and clinical significance of potential drug–drug interaction in hematopoietic stem cell transplantation. Cancer Chemother Pharmacol. 2015;75:393–400.PubMedCrossRef Trevisan DD, Silva JB, Oliveira HC, Secoli SR, Lima MH. Prevalence and clinical significance of potential drug–drug interaction in hematopoietic stem cell transplantation. Cancer Chemother Pharmacol. 2015;75:393–400.PubMedCrossRef
25.
go back to reference Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53:24–34.PubMedCrossRef Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53:24–34.PubMedCrossRef
26.
go back to reference Brüggemann RJ, Alffenaar JW, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48:1441–58.PubMedCrossRef Brüggemann RJ, Alffenaar JW, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48:1441–58.PubMedCrossRef
27.
go back to reference Tay KY, Ewald MB, Bourgeois FT. Use of QT-prolonging medications in US emergency departments, 1995–2009. Pharmacoepidemiol Drug Saf. 2014;23:9–17.PubMedCrossRef Tay KY, Ewald MB, Bourgeois FT. Use of QT-prolonging medications in US emergency departments, 1995–2009. Pharmacoepidemiol Drug Saf. 2014;23:9–17.PubMedCrossRef
28.
go back to reference Lin YL, Hsiao CL, Wu YC, Kung MF. Electrophysiologic, pharmacokinetic, and pharmacodynamic values indicating a higher risk of torsades de pointes. J Clin Pharmacol. 2011;51:819–29.PubMedCrossRef Lin YL, Hsiao CL, Wu YC, Kung MF. Electrophysiologic, pharmacokinetic, and pharmacodynamic values indicating a higher risk of torsades de pointes. J Clin Pharmacol. 2011;51:819–29.PubMedCrossRef
29.
go back to reference Lin YL, Kung MF. Magnitude of QT prolongation associated with a higher risk of torsades de pointes. Pharmacoepidemiol Drug Saf. 2009;18:235–9.PubMedCrossRef Lin YL, Kung MF. Magnitude of QT prolongation associated with a higher risk of torsades de pointes. Pharmacoepidemiol Drug Saf. 2009;18:235–9.PubMedCrossRef
30.
go back to reference Jardin CG, Putney D, Michaud S. Assessment of drug-induced torsade de pointes risk for hospitalized high-risk patients receiving QT-prolonging agents. Ann Pharmacother. 2014;48:196–202.PubMedCrossRef Jardin CG, Putney D, Michaud S. Assessment of drug-induced torsade de pointes risk for hospitalized high-risk patients receiving QT-prolonging agents. Ann Pharmacother. 2014;48:196–202.PubMedCrossRef
32.
go back to reference Woosley RL, Romero K. Assessing cardiovascular drug safety for clinical decision-making. Nat Rev Cardiol. 2013;10:330–7.PubMedCrossRef Woosley RL, Romero K. Assessing cardiovascular drug safety for clinical decision-making. Nat Rev Cardiol. 2013;10:330–7.PubMedCrossRef
33.
go back to reference Walsh T, Anaissie E, Denning D, Herbrecht R, Kontoyiannis D, Marr K, Morrison V, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–60.PubMedCrossRef Walsh T, Anaissie E, Denning D, Herbrecht R, Kontoyiannis D, Marr K, Morrison V, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–60.PubMedCrossRef
34.
35.
go back to reference Schneider T, Halter J, Heim D, Passweg J, Stern M, Tichelli A, et al. Pre-emptive diagnosis and treatment of fungal infections—evaluation of a single-centre policy. Clin Microbiol Infect. 2012;18:189–94.PubMedCrossRef Schneider T, Halter J, Heim D, Passweg J, Stern M, Tichelli A, et al. Pre-emptive diagnosis and treatment of fungal infections—evaluation of a single-centre policy. Clin Microbiol Infect. 2012;18:189–94.PubMedCrossRef
Metadata
Title
Drug utilization study of systemic antifungal agents in a Brazilian tertiary care hospital
Authors
Maria Clara Padovani de Souza
Andrezza Gouvêa dos Santos
Adriano Max Moreira Reis
Publication date
01-12-2016
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 6/2016
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-016-0382-6

Other articles of this Issue 6/2016

International Journal of Clinical Pharmacy 6/2016 Go to the issue